Lilly to Expand Oncology Capabilities with POINT Biopharma Acquisition
Elly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreOrano Med, a clinical-stage biotechnology company that develops the next generation of targeted therapies against cancer using the unique properties
Read morePeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kanagawa, Japan, led by President and CEO Patrick C. Reid, has
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read moreCustomized Bioconjugation Solutions for Pharma and IVD Industries Biosynth, a pivotal supplier of vital raw materials to the life science
Read moreBiosynth, a leading supplier of critical raw materials to the life science industry, is pleased to announce its recent acquisition
Read moreAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) and PeptiDream Inc. (TSE: 4587, President and CEO: Patrick C.
Read moreWatlow®, a pioneering industrial thermal systems designer and manufacturer, is elevating its digital transformation of energy management and automation solutions
Read moreEli Lilly and Company and DICE Therapeutics, Inc. have signed a definitive agreement for Lilly to acquire DICE for approximately $2.4
Read moreThe $1 billion acquisition deal is set to advance Ironwood’s vision of becoming the leading gastrointestinal healthcare company. Ironwood Pharmaceuticals,
Read more